<DOC>
	<DOCNO>NCT00468429</DOCNO>
	<brief_summary>This study analyze safety efficacy off-label Subconjunctival Injection bevacizumab ( Avastin ) versus 0.02 % mitomycin C ( MMC ) prevent bleb failure follow glaucoma filtration surgery .</brief_summary>
	<brief_title>Subconjunctival Bevacizumab Prevent Bleb Failure After Glaucoma Filtration Surgery</brief_title>
	<detailed_description>Glaucoma Filtration Surgery ( GFS ) remain definitive surgical management elevate IOL uncontrolled medical management . Bleb failure major factor limit longterm success trabeculectomy surgery . Bleb failure involve vascularization fibroblast migration eventual scarring fistula tract . Vascular Endothelial Growth Factor ( VEGF ) unique mitogen specific vascular endothelial cell signal cascade lead fibroblast migration proliferation involve dynamic interaction many protein . Blocking neovascular signal cascade anti-VEGF molecule like Bevacizumab may lead decrease fibroblast proliferation decrease supply mitogenic cytokine fibroblast growth factor ( FGF ) carry new vessel formation decrease know synergism exist VEGF fibroblast growth factor ( FGF ) The study design off-label , randomize , parallel , comparative study . Patients meet inclusion/exclusion criterion sign inform consent include . After enrollment , patient randomize two group : trabeculectomy off-label subconjunctival bevacizumab trabeculectomy mitomycin-C.This study aim compare safety effectiveness off-label subconjunctival bevacizumab subtenon Mitomycin C glaucoma filtration surgery ( GFS ) . The primary endpoint prove effectiveness via reduction IOP grade bleb photograph accord Moorfields Bleb Grading Protocol , secondary endpoint prove safety via incidence complication adverse event . Procedure : Surgical technique Trabeculectomy perform administration retrobulbar peribulbar anesthesia lidocaine . For limbus-based procedure , bridle suture ( 4–0 silk ) place superior rectus muscle tendon , conjunctiva Tenon ’ capsule incise superior quadrant 8 10 mm posterior surgical limbus . The conjunctiva Tenon ’ capsule dissect anterior limbus . Meticulous hemostasis achieve bipolar cautery . In case randomize MMC usage , cellulose sponge ( approximately 6 × 12 mm × 1 mm ) soak mitomycin C ( 0.2 mg/ml ) apply intend site scleral flap 1 3 minute . The duration mitomycin C application base preoperative evaluation patient ’ risk factor failure . Copious irrigation balance salt solution perform wash away residual MMC . A ½ 2/3 thickness square scleral flap ( approximately 3.5 × 3.5 mm ) dissect clear cornea . After resection anterior trabecular block ( approximately 2.5 × 1 mm ) , iridectomy perform . The scleral flap suture two three 10–0 nylon suture corner . The conjunctiva Tenon ’ capsule close single continuous layer 8–0 Vicryl suture . In subject randomize receive Injection Bevacizumab , 0.05 ml reconstitute bevacizumab drug ( 1.25 mg ) inject subconjunctivally adjacent bleb . Atropine eye ointment place fornix eye patch . In early postoperative period , patient treat topical corticosteroid ( four time daily ) two week , tapered-off slowly six eight week . Suture-lysis argon laser perform topical anesthesia , opinion surgeon , filtration judge low IOP high patient meet target pressure . Preparation Drug : Bevacizumab Avastin ( Avastin ) available sterile vial ( 100 mg 4 ml ) preservative free order ensure safety vial injection administer within one day . Subconjunctival Injections ( 1.25mg drug 0.05ml ) give end surgery adjacent bleb raise use single-use 30-gauge needle tuberculin syringe . Follow-Up : The following demographic clinical data extract medical record eligible patient : race , age patient time surgery , gender , eye laterality , preoperative visual acuity , refractive error , average IOP reading three month surgery , number medication record three month precede trabeculectomy , concurrent ocular disease time surgery , history intraocular extraocular surgery involve conjunctiva , previous laser surgery glaucoma ( argon laser trabeculoplasty , iridoplasty , peripheral iridotomy ) , visual field mean deviation last field surgery , date surgery , type conjunctival flap , concentration duration mitomycin C application , site dose subconjunctival Bevacizumab injection intraoperative complication . Postoperative IOP , number medication , visual acuity , complication , postoperative suture lysis , surgery perform trabeculectomy record . At visit , examination include measurement Snellen best correct visual acuity ( BCVA ) , IOP use calibrate applanation tonometer , slit-lamp biomicroscopy , Seidel test , ophthalmoscopy . Humphrey perimetry ( 24-2 10-2 ) do prior surgery , 3 6 month post intervention ass objective disease progression . There 7 post-operative follow-up visit within 6 month surgery : postoperative day 1 , 7 , 14 , 30 , 60 , 90 180 . A window ± 7 day allow 30 , 60 , 90 day visit ± 14 day 180 day visit . On visit Bleb photograph would record graded accord Moorfields Bleb Grading Protocol single observer . Outcomes : Complete success define IOP &lt; 18mmHg without anti- glaucoma medication 6 month follow surgery least 20 % reduction baseline IOP . Qualified Success define IOP &lt; 18mmHg one anti-glaucoma medication . Failure define IOP &gt; 21 mmHg reduce 20 % baseline two consecutive follow-up visit three month despite medication , IOP ≤5 mmHg two consecutive follow-up visit three month , additional glaucoma surgery , loss light perception . Eyes Seidel positive within first month follow-up classify wound leak , occur one month categorize bleb leak . Cataracts consider progressed loss ≥2 line Snellen BCVA attribute cataract six-month follow-up visit , cataract surgery perform . Statistical analysis Univariate comparison treatment group make two-sided Student test , χ2 test , Fisher exact test . The association surgical complication treatment outcome , vision loss , cataract progression assess statistical significance χ2 test Fisher exact test . A p value .05 le consider statistically significant .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>1 . Age 40 year . 2 . Patient uncontrolled intraocular pressure maximum tolerate medical therapy ( primary open angle primary angle closure glaucoma ) , require trabeculectomy . 3 . Indications surgery base practice pattern : ( 1 ) IOP value associate high probability glaucoma progression ( 2 ) deterioration visual field change optic disk compatible progressive glaucomatous damage , judge examine physician . 4 . No history prior surgical procedure like trabeculectomy , cataract surgery , posterior segment surgery etc . 5 . Subject able willing cooperate investigation plan . 6 . Subject able willing complete postoperative followup requirement . 7 . Subject willing sign inform consent form . 1 . Known allergic reaction mitomycinC/ bevacizumab . 2 . Subject warfarin discontinuation recommend . 3 . Normal tension glaucoma . 4 . Participation investigational study 30 day precede trabeculectomy 5 . Patients undergone major surgery utpo 28 day . 6 . Ocular infection within 14 day prior trabeculectomy . 7 . Pregnant breastfeed woman . 8 . Patients uncontrolled diabetes hypertension medical condition increase risk complication</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Glaucoma Filtration Surgery</keyword>
	<keyword>Mitomycin C</keyword>
	<keyword>Intraocular Pressure</keyword>
</DOC>